Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Emerge Weight Loss vs myRocky

Emerge Weight Loss
Graded #448

Higher grade

vs+3.700000000000003
myRocky
Graded #487

Lower grade

The verdict

Emerge Weight Loss takes it — 55.1/100 to 51.4/100.

Emerge Weight Loss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Emerge Weight Loss is a nationwide telehealth platform focused specifically on compounded tirzepatide for medical weight management.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmerge Weight Loss +2
36
34
Dose & formulationmyRocky +11
42
53
Clinical oversightEmerge Weight Loss +20
84
64
Labs & monitoringEmerge Weight Loss +2
54
52
FulfillmentEven
70
70
Contract termsEmerge Weight Loss +14
55
41
Emerge Weight Loss · left barmyRocky · right bar

The numbers

MetricEmerge Weight LossmyRocky
WeighScore55.1/10051.4/100
GradeCC
Scorecard rank#448#487
SemaglutideNot disclosedNot disclosed
Tirzepatide$287/mo (2.5 mg dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Emerge Weight Loss

Graded #448 · C

Strengths

  • Tirzepatide-focused (largest effect-size compounded GLP-1)
  • Wide dose range available
  • Physician-supervised telemedicine model

Where it loses points

  • Semaglutide is available only on request — the site and default plans are tirzepatide-only
  • Less brand recognition than Henry Meds, Mochi, or SkinnyRx
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard